Penicillamine for treating rheumatoid arthritis-Reference-Cited by-同舟云学术

Penicillamine for treating rheumatoid arthritis

Published:2000-10-23 Issue:10 Volume:2011 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Suarez-Almazor Maria E¹,Belseck Elaine²,Spooner Carol³

Affiliation:

1. The University of Texas, M.D. Anderson Cancer Center; Department of General Internal Medicine; 1515 Holcombe Blvd Unit 1465 Houston Texas USA 77030

2. University of Alberta; Department of Pediatrics; 2C3.67 Walter C Mackenzie Alberta Canada T6G 2R7

3. 1G1.52 Walter Mackenzie Health Centre; Division of Emergency Medicine; 8440 - 112 ST Edmonton Alberta Canada T6G 2B7

Publisher

Wiley

Subject

Pharmacology (medical)

Reference33 articles.

1. Controlled trial of d-Penicillamine in severe rheumatoid arthritis;Multicentre Trial Group;Lancet,1973

2. J, Davies J, Dormandy TL, Hamilton EBD, Holt PJL, Mason RM, Thompson M, Weber JCP, Zutshi DW. Synthetic d-penicillamine in rheumatoid arthritis. Double-blind controlled study of a high and low dosage regimen;Dixon;Ann Rheum Dis,1975

3. Multicenter trial with synthetic D-penicillamine in rheumatoid arthritis;Hamilton,1977

4. Immunostimulant therapy with levamisole for rheumatoid arthritis;Huskisson;Lancet,1976

5. Controlled trial of d-penicillamine in rheumatoid arthritis;Mery;Scand J Rheumatology,1976

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monotreatment With Conventional Antirheumatic Drugs or Glucocorticoids in Rheumatoid Arthritis;JAMA Network Open;2023-10-06

2. Two-Dimensional Chiroptically Active Copper Oxide Nanostructures;The Journal of Physical Chemistry C;2022-10-27

3. Molecular Basis for the Interaction of Catalase with d-Penicillamine: Rationalization of Some of Its Deleterious Effects;Chemical Research in Toxicology;2022-02-22

4. From NSAIDs to Glucocorticoids and Beyond;Cells;2021-12-14

5. Safety profile of D-penicillamine: a comprehensive pharmacovigilance analysis by FDA adverse event reporting system;Expert Opinion on Drug Safety;2021-07-26